Figure 1 | International Journal of Impotence Research

Figure 1

From: A double-blind, randomised- placebo, controlled, parallel group, multicentre, flexible-dose escalation study to assess the efficacy and safety of sildenafil administered as required to male outpatients with erectile dysfunction in Korea

Figure 1

Mean scores, as percentages of the maximum IIEF scores, at baseline and following 12 weeks of sildenafil or placebo administration for the primary efficacy variables: (1) frequency of penetration (IIEF question 3) and (2) frequency of maintained erection after penetration (IIEF question 4). For both questions, scores were available for 110 patients receiving sildenafil and for 111 receiving placebo. *P<0.0001 versus placebo.

Back to article page